

Information from Vitrolife's Election Committee

Board member Jón Sigurdsson is proposed as new Chairman of the Board of Vitrolife AB (publ).

The Election Committee proposes the following for the Annual General Meeting of Vitrolife on Thursday, 2 May 2019:

- that the Board shall consist of five Board members.
- re-election of Board members Barbro Fridén, Lars Holmqvist, Pia Marions and Jón Sigurdsson and election of the new Board member Henrik Blomquist, CEO Bure Equity AB. Carsten Browall has declined re-election.
- Election of Jón Sigurdsson as Chairman of the Board, member of Vitrolife's Board since 2015.

"Carsten Browall has declined re-election after seven years on the Board, of which six years as Chairman of the Board. During Carsten's chairmanship, the company's market value has increased from approximately SEK 1.5 billion to approximately SEK 20 billion. The Election Committee wishes to thank Carsten Browall for an extraordinary work and welcomes Jón Sigurdsson as the new Chairman of the Board," says Patrik Tigerschiöld, Chairman of the Election Committee.

The Election Committee's other proposals will be published in the notice of the Annual General Meeting, which is expected to be published at the end of March.

Gothenburg, February 25, 2019
VITROLIFE AB (publ)

Queries should be addressed to:

Patrik Tigerschiöld, Chairman of the Election Committee, phone 46 8 614 00 20
Carsten Browall, Chairman of the Board, phone 46 70 255 65 32

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets products for assisted reproduction. Vitrolife today has approximately 390 employees and the company's products are sold in approximately 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 99.
E-mail: info@vitrolife.com. Website: www.vitrolife.com.

This information is information that Vitrolife AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on February 25, 2019.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.